Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review

Código QR

Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review

Helen Berlie, Kathryn M Hurren, Nicole R PinelliEugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USAAbstract: The prevalence of obesity and diabetes continues to rise in the US. Glucagon-like peptide-1 receptor agonist (GLP-1RA) is an effective treatment...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Berlie H, Hurren KM, Pinelli NR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/fcaeb1feba014228bd09a1d02c9d7fcd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung T, et al.
Publicado: (2015)

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
por: Levin PA, et al.
Publicado: (2017)

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
por: Courtney H, et al.
Publicado: (2017)

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
por: Wang F, et al.
Publicado: (2012)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
por: Minara S. Shamkhalova, et al.
Publicado: (2020)

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE–/– Mice
por: Liu F, et al.
Publicado: (2020)

Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: central plus peripheral nervous system mechanisms
por: Fuad Lechin, et al.
Publicado: (2009)

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe S, et al.
Publicado: (2011)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chee&nbsp;W Chia, et al.
Publicado: (2009)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Lisa M Neff, et al.
Publicado: (2010)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
por: Gagik R. Galstyan, et al.
Publicado: (2017)

Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
por: Kedia N
Publicado: (2011)

Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis
por: Kostev K, et al.
Publicado: (2015)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
por: Stolar MW, et al.
Publicado: (2013)

Insulin-Like Proteins in Plant Sources: A Systematic Review
por: Costa IS, et al.
Publicado: (2020)

Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience
por: Chan WB, et al.
Publicado: (2017)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau IT, et al.
Publicado: (2017)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
por: Lee J, et al.
Publicado: (2019)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
por: Nina A. Petunina, et al.
Publicado: (2018)

Insulin glulisine in the management of diabetes
por: Satoru Yamada
Publicado: (2009)

Systematic review of clinical studies related to pork intake and metabolic syndrome or its components
por: Stettler N, et al.
Publicado: (2013)

Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes
por: Mackenzie RWA, et al.
Publicado: (2014)

Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
por: Kalirai S, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Wang N, et al.
Publicado: (2019)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
por: Marina V. Shestakova, et al.
Publicado: (2017)

Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage [Corrigendum]
por: Wilke T, et al.
Publicado: (2019)

TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity
por: Zambad SP, et al.
Publicado: (2013)

Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity
por: Bruckbauer A, et al.
Publicado: (2013)

Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
por: Sinha B, et al.
Publicado: (2014)

Relationship between insulin resistance and plasma vitamin D in adults
por: Badawi A, et al.
Publicado: (2014)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander PA
Publicado: (2012)

Association of adiponectin levels and insulin demand in critically ill patients
por: Andreas Hillenbrand, et al.
Publicado: (2011)

Negative association of acetate with visceral adipose tissue and insulin levels
por: Layden BT, et al.
Publicado: (2012)

Adipose inflammation: cause or consequence of obesity-related insulin resistance
por: Haiyan Xu, et al.
Publicado: (2008)

Evaluation of the relationship between the pelvic floor muscles and insulin resistance
por: Micussi MT, et al.
Publicado: (2015)

Insulin initiation and intensification in patients with T2DM for the primary care physician
por: Unger J
Publicado: (2011)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Stanley S Schwartz
Publicado: (2010)

Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia
por: Yanay O, et al.
Publicado: (2015)

The effects of diet- and diet plus exercise-induced weight loss on basal metabolic rate and acylated ghrelin in grade 1 obese subjects
por: Lopes AL, et al.
Publicado: (2013)